EP
RYTM icon

Eudaimonia Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Eudaimonia Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$21K – 1172
2021
Q1 		$21K Hold
1,000
– – ﹤0.01% 924
2020
Q4 		$30K Hold
1,000
– – 0.01% 761
2020
Q3 		$22K Buy
+1,000
New +$22.9K 0.01% 777

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eudaimonia Partners's RYTM Position: Q2 2021 in Review

Eudaimonia Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2021, closing a stake of 1,000 shares — an estimated $21K sold.

Eudaimonia Partners first reported a position in RYTM in Q3 2020 and held it in 3 quarters. The position peaked at $30K in Q4 2020. 105 funds tracked by Wall St. Rank hold RYTM as of Q2 2021.

  • Eudaimonia Partners reported no remaining Rhythm Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 1,000 Rhythm Pharmaceuticals shares in Q2 2021, an estimated $21K.
  • Eudaimonia Partners first reported a position in Rhythm Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Eudaimonia Partners's Rhythm Pharmaceuticals position peaked at $30K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.